

# Heiner K Berthold

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3093026/publications.pdf>

Version: 2024-02-01

124  
papers

6,447  
citations

109311

35  
h-index

69246

77  
g-index

132  
all docs

132  
docs citations

132  
times ranked

8775  
citing authors

#	ARTICLE	IF	CITATIONS
1	Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. <i>American Journal of Clinical Nutrition</i> , 2006, 83, 754-759.	4.7	828
2	Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. <i>American Journal of Clinical Nutrition</i> , 2009, 89, 1321-1327.	4.7	469
3	Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure?. <i>Journal of the American College of Cardiology</i> , 2003, 41, 105-112.	2.8	459
4	Low to moderate sugar-sweetened beverage consumption impairs glucose and lipid metabolism and promotes inflammation in healthy young men: a randomized controlled trial. <i>American Journal of Clinical Nutrition</i> , 2011, 94, 479-485.	4.7	303
5	Body Fat Distribution, Serum Leptin, and Cardiovascular Risk Factors in Men With Obstructive Sleep Apnea. <i>Chest</i> , 2002, 122, 829-839.	0.8	297
6	Policosanol: Clinical pharmacology and therapeutic significance of a new lipid-lowering agent. <i>American Heart Journal</i> , 2002, 143, 356-365.	2.7	205
7	Molecular Lipids Identify Cardiovascular Risk and Are Efficiently Lowered by Simvastatin and PCSK9 Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E45-E52.	3.6	180
8	Effect of a Garlic Oil Preparation on Serum Lipoproteins and Cholesterol Metabolism. <i>JAMA - Journal of the American Medical Association</i> , 1998, 279, 1900.	7.4	175
9	Physician gender is associated with the quality of type 2 diabetes care. <i>Journal of Internal Medicine</i> , 2008, 264, 340-350.	6.0	164
10	Sex Disparities in the Treatment and Control of Cardiovascular Risk Factors in Type 2 Diabetes. <i>Diabetes Care</i> , 2008, 31, 1389-1391.	8.6	156
11	Effect of Policosanol on Lipid Levels Among Patients With Hypercholesterolemia or Combined Hyperlipidemia. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 2262.	7.4	148
12	Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily. <i>European Heart Journal</i> , 2017, 38, 2279-2286.	2.2	134
13	IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans. <i>Journal of Lipid Research</i> , 2015, 56, 1034-1042.	4.2	114
14	Effects of Lipid-Lowering Drugs on Irisin in Human Subjects In Vivo and in Human Skeletal Muscle Cells Ex Vivo. <i>PLoS ONE</i> , 2013, 8, e72858.	2.5	104
15	Vitamin D and Cardiovascular Disease. <i>Current Vascular Pharmacology</i> , 2009, 7, 414-422.	1.7	103
16	5,10-Methylenetetrahydrofolate reductase genotype determines the plasma homocysteine-lowering effect of supplementation with 5-methyltetrahydrofolate or folic acid in healthy young women. <i>American Journal of Clinical Nutrition</i> , 2002, 75, 275-282.	4.7	94
17	Influence of protease inhibitor therapy on lipoprotein metabolism. <i>Journal of Internal Medicine</i> , 1999, 246, 567-575.	6.0	81
18	Sex- and Gender-Based Pharmacological Response to Drugs. <i>Pharmacological Reviews</i> , 2021, 73, 730-762.	16.0	80

#	ARTICLE	IF	CITATIONS
19	Effect of Ezetimibe and/or Simvastatin on Coenzyme Q10 Levels in Plasma. <i>Drug Safety</i> , 2006, 29, 703-712.	3.2	78
20	Comparison of the hepatic clearances of campesterol, sitosterol, and cholesterol in healthy subjects suggests that efflux transporters controlling intestinal sterol absorption also regulate biliary secretion. <i>Gut</i> , 2002, 51, 860-863.	12.1	71
21	Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients. <i>Clinical Transplantation</i> , 2007, 21, 536-543.	1.6	68
22	Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. <i>European Heart Journal</i> , 2010, 31, 1633-1639.	2.2	65
23	Uniformly <sup>13</sup> C-labeled algal protein used to determine amino acid essentiality in vivo.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 8091-8095.	7.1	64
24	A randomized controlled trial on the efficacy of carbohydrate-reduced or fat-reduced diets in patients attending a telemedically guided weight loss program. <i>Cardiovascular Diabetology</i> , 2009, 8, 36.	6.8	63
25	Lipoprotein(a) Concentration Increases during Treatment with Carbamazepine. <i>Epilepsia</i> , 2003, 44, 457-460.	5.1	60
26	Lipoprotein metabolism in patients with anorexia nervosa: a case-control study investigating the mechanisms leading to hypercholesterolaemia. <i>British Journal of Nutrition</i> , 2004, 91, 959-969.	2.3	59
27	Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: A randomized trial in healthy men. <i>Atherosclerosis</i> , 2008, 198, 198-207.	0.8	55
28	Evidence from a Randomized Trial That Simvastatin, but Not Ezetimibe, Upregulates Circulating PCSK9 Levels. <i>PLoS ONE</i> , 2013, 8, e60095.	2.5	54
29	Immunosuppressive Therapy with Everolimus Can Be Associated with Potentially Life-Threatening Lingual Angioedema. <i>Transplantation</i> , 2005, 79, 981-983.	1.0	46
30	Supplementation with a multivitamin containing 800 µg of folic acid shortens the time to reach the preventive red blood cell folate concentration in healthy women. <i>International Journal for Vitamin and Nutrition Research</i> , 2009, 79, 61-70.	1.5	45
31	Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men. <i>Clinical Endocrinology</i> , 2008, 68, 536-541.	2.4	44
32	Patterns and predictors of statin prescription in patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2009, 8, 25.	6.8	42
33	Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia. <i>Atherosclerosis Supplements</i> , 2015, 18, 28-34.	1.2	41
34	Leucine Oxidation Changes Rapidly after Dietary Protein Intake is Altered in Adult Women but Lysine Flux Is Unchanged As Is Lysine Incorporation into VLDL-Apolipoprotein B-100. <i>Journal of Nutrition</i> , 1994, 124, 41-51.	2.9	36
35	Heat Shock Protein-60 and Risk for Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2011, 17, 3662-3668.	1.9	36
36	Influence of serum selenium concentrations on hypertension. <i>Journal of Hypertension</i> , 2012, 30, 1328-1335.	0.5	35

#	ARTICLE	IF	CITATIONS
37	Association between the PPAR $\alpha$ L162V polymorphism, plasma lipoprotein levels, and atherosclerotic disease in patients with diabetes mellitus type 2 and in nondiabetic controls. <i>American Heart Journal</i> , 2004, 147, 1117-1124.	2.7	34
38	Comparison of a silicon carbide-coated stent versus a noncoated stent in human beings: The Tenax versus Nir Stent Study's long-term outcome. <i>American Heart Journal</i> , 2003, 145, E17.	2.7	33
39	Short-term effects of high soy supplementation on sex hormones, bone markers, and lipid parameters in young female adults. <i>European Journal of Nutrition</i> , 2004, 43, 100-108.	3.9	33
40	Garlic preparations for prevention of atherosclerosis. <i>Current Opinion in Lipidology</i> , 1998, 9, 565-569.	2.7	33
41	Age-dependent effects of atorvastatin on biochemical bone turnover markers: a randomized controlled trial in postmenopausal women. <i>Osteoporosis International</i> , 2004, 15, 459-67.	3.1	32
42	The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 317, E411-E420.	3.5	32
43	Troglitazone and rosiglitazone induce apoptosis of vascular smooth muscle cells through an extracellular signal-regulated kinase-independent pathway. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2001, 363, 215-221.	3.0	31
44	Body mass index and disease duration are predictors of disturbed bone turnover in anorexia nervosa. A case-control study. <i>European Journal of Clinical Nutrition</i> , 2003, 57, 1262-1267.	2.9	31
45	Association between the Interleukin-6 Promoter Polymorphism $\alpha$ 174G/C and Serum Lipoprotein(a) Concentrations in Humans. <i>PLoS ONE</i> , 2011, 6, e24719.	2.5	31
46	Evidence for incorporation of intact dietary pyrimidine (but not purine) nucleosides into hepatic RNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995, 92, 10123-10127.	7.1	30
47	Isotopic evidence for the differential regulation of arginine and proline synthesis in man. <i>Metabolism: Clinical and Experimental</i> , 1995, 44, 466-473.	3.4	30
48	The peroxisome proliferator-activated receptor delta +294T/C polymorphism in relation to lipoprotein metabolism in patients with diabetes mellitus type 2 and in non-diabetic controls. <i>Atherosclerosis</i> , 2005, 183, 336-341.	0.8	30
49	Comparison of a Silicon Carbide Coated Stent versus a Noncoated Stent in Humans. <i>Journal of Interventional Cardiology</i> , 2003, 16, 325-333.	1.2	29
50	Lipid-lowering Drug Therapy in Elderly Patients. <i>Current Pharmaceutical Design</i> , 2011, 17, 877-893.	1.9	29
51	Lipoprotein(a): Current Perspectives. <i>Current Vascular Pharmacology</i> , 2011, 9, 682-692.	1.7	28
52	Resistin gene 3'-untranslated region +62GA polymorphism is associated with hypertension but not diabetes mellitus type 2 in a German population. <i>Journal of Internal Medicine</i> , 2005, 258, 518-526.	6.0	26
53	The whey fermentation product malleable protein matrix decreases TAG concentrations in patients with the metabolic syndrome: a randomised placebo-controlled trial. <i>British Journal of Nutrition</i> , 2012, 107, 1694-1706.	2.3	26
54	Carbamazepine increases atherogenic lipoproteins: mechanism of action in male adults. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002, 282, H704-H716.	3.2	25

#	ARTICLE	IF	CITATIONS
55	Peroxisome proliferator-activated receptor- $\alpha$ Pro12Ala and endothelial nitric oxide synthase-4a/b gene polymorphisms are not associated with hypertension in diabetes mellitus type 2. <i>Journal of Hypertension</i> , 2005, 23, 301-308.	0.5	24
56	The Leu72Met polymorphism of the ghrelin gene is associated with a decreased risk for type 2 diabetes. <i>Clinica Chimica Acta</i> , 2009, 399, 112-116.	1.1	24
57	The effect of vitamin D on fibroblast growth factor 23: a systematic review and meta-analysis of randomized controlled trials. <i>European Journal of Clinical Nutrition</i> , 2021, 75, 980-987.	2.9	24
58	Lymphocyte proliferation and apoptosis in HIV-seropositive and healthy subjects during long-term ingestion of fruit juices or a fruit-vegetable-concentrate rich in polyphenols and antioxidant vitamins. <i>European Journal of Clinical Nutrition</i> , 2004, 58, 317-325.	2.9	23
59	Adverse Reactions to Anticoagulants and to Antiplatelet Drugs Recorded by the German Spontaneous Reporting System. <i>Seminars in Thrombosis and Hemostasis</i> , 2005, 31, 371-380.	2.7	22
60	Bolus ingestion of white and green tea increases the concentration of several flavanols in plasma, but does not affect markers of oxidative stress in healthy non-smokers. <i>Molecular Nutrition and Food Research</i> , 2010, 54, 1636-1645.	3.3	22
61	Influence of ghrelin gene polymorphisms on hypertension and atherosclerotic disease. <i>Hypertension Research</i> , 2010, 33, 155-160.	2.7	22
62	Low serum levels of intact osteocalcin in patients with congestive heart failure. <i>Journal of Bone and Mineral Metabolism</i> , 2003, 21, 247-52.	2.7	22
63	Hyperlipoproteinemia(a): Clinical significance and treatment options. <i>Atherosclerosis Supplements</i> , 2013, 14, 1-5.	1.2	20
64	PCSK9 Antibodies for the Treatment of Hypercholesterolemia. <i>Nutrients</i> , 2014, 6, 5517-5533.	4.1	20
65	Effects of Vitamin D Supplementation on Renin and Aldosterone Concentrations in Patients with Advanced Heart Failure: The EVITA Trial. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-10.	1.5	20
66	5-HT1 receptor agonists attenuate the naloxone-induced jumping behaviour in morphine-dependent mice. <i>European Journal of Pharmacology</i> , 1989, 162, 19-27.	3.5	18
67	SREBP-1c Gene Polymorphism is Associated with Increased Inhibition of Cholesterol-Absorption in Response to Ezetimibe Treatment. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2008, 116, 262-267.	1.2	18
68	Use of the lactose-[13C]ureide breath test for diagnosis of small bowel bacterial overgrowth: comparison to the glucose hydrogen breath test. <i>Journal of Gastroenterology</i> , 2009, 44, 944-951.	5.1	18
69	Antisense Oligonucleotides for the Treatment of Dyslipidemia. <i>Current Pharmaceutical Design</i> , 2011, 17, 950-960.	1.9	18
70	Vitamin D and Vascular Disease. <i>Current Vascular Pharmacology</i> , 2020, 19, 250-268.	1.7	18
71	Decrease of elevated N,N-dimethylglycine and N-methylglycine in human immunodeficiency virus infection during short-term highly active antiretroviral therapy. <i>Metabolism: Clinical and Experimental</i> , 2001, 50, 1275-1281.	3.4	17
72	Plasma antioxidant capacity of HIV-seropositive and healthy subjects during long-term ingestion of fruit juices or a fruit-vegetable-concentrate containing antioxidant polyphenols. <i>European Journal of Clinical Nutrition</i> , 2001, 55, 786-792.	2.9	17

#	ARTICLE	IF	CITATIONS
73	Carbamazepine Does Not Alter Biochemical Parameters of Bone Turnover in Healthy Male Adults. <i>Calcified Tissue International</i> , 2003, 73, 356-360.	3.1	17
74	Combined calcium and vitamin D supplementation is not superior to calcium supplementation alone in improving disturbed bone metabolism in patients with congestive heart failure. <i>European Journal of Clinical Nutrition</i> , 2008, 62, 1388-1394.	2.9	17
75	Designing a study to evaluate the effect of apheresis in patients with elevated lipoprotein(a). <i>Atherosclerosis Supplements</i> , 2009, 10, 85-88.	1.2	16
76	Antidiuretic effect of Sandostatin® (SMS 201-995) in healthy volunteers. <i>European Journal of Endocrinology</i> , 1989, 120, 708-714.	3.7	15
77	Improvement of sarcoidosis under therapy with interferon- $\beta$ 2b for chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 1999, 30, 347.	3.7	15
78	Troglitazone and rosiglitazone inhibit the low density lipoprotein-induced vascular smooth muscle cell growth. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2001, 109, 203-209.	1.2	15
79	Physiologic Fluctuations of Serum Estradiol Levels Influence Biochemical Markers of Bone Resorption in Young Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 95-101.	3.6	15
80	Disease management programs in type 2 diabetes: quality of care. <i>American Journal of Managed Care</i> , 2011, 17, 393-403.	1.1	15
81	Association of the promoter polymorphism -232C/G of the phosphoenolpyruvate carboxykinase gene (PCK1) with Type 2 diabetes mellitus. <i>Diabetic Medicine</i> , 2006, 23, 419-425.	2.3	14
82	The K121Q Polymorphism of the Plasma Cell Glycoprotein-1 Gene is not Associated with Diabetes Mellitus Type 2 in German Caucasians. <i>Hormone and Metabolic Research</i> , 2006, 38, 524-529.	1.5	14
83	Effect of a Cellulose-containing Weight-loss Supplement on Gastric Emptying and Sensory Functions. <i>Obesity</i> , 2008, 16, 2272-2280.	3.0	14
84	Effects of simvastatin and ezetimibe on interleukin-6 and high-sensitivity C-reactive protein. <i>Scandinavian Cardiovascular Journal</i> , 2013, 47, 20-27.	1.2	14
85	The Role of Niacin in Lipid-lowering Treatment: Are we Aiming Too High?. <i>Current Pharmaceutical Design</i> , 2013, 19, 3094-3106.	1.9	14
86	The Pro387Leu variant of protein tyrosine phosphatase-1B is not associated with diabetes mellitus type 2 in a German population. <i>Journal of Internal Medicine</i> , 2005, 257, 272-280.	6.0	13
87	The stable isotope ketoisocaproic acid breath test as a measure of hepatic decarboxylation capacity: a quantitative analysis in normal subjects after oral and intravenous administration. <i>Liver International</i> , 2009, 29, 1356-1364.	3.9	13
88	Effects of authentic and VLDL hydrolysis-derived fatty acids on vascular smooth muscle cell growth. <i>British Journal of Pharmacology</i> , 2001, 132, 1725-1734.	5.4	12
89	Lomitapide for use in patients with homozygous familial hypercholesterolemia: a narrative review. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 655-663.	3.1	12
90	Vitamin D supplementation and bone turnover in advanced heart failure: the EVITA trial. <i>Osteoporosis International</i> , 2018, 29, 579-586.	3.1	12

#	ARTICLE	IF	CITATIONS
91	Vitamin D supplementation does not prevent the testosterone decline in males with advanced heart failure: the EVITA trial. <i>European Journal of Nutrition</i> , 2019, 58, 673-680.	3.9	12
92	Inhibition of the 5-HT-induced cardiogenic hypertensive chemoreflex by the selective 5-HT <sub>3</sub> receptor antagonist ICS 205-930. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1989, 339, 259-62.	3.0	11
93	High-dose oral supplementation of antioxidants and glutamine improves the antioxidant status in patients with Crohn's disease: A pilot study. <i>European E-journal of Clinical Nutrition and Metabolism</i> , 2008, 3, e246-e253.	0.4	11
94	The whey fermentation product malleable protein matrix decreases triglyceride concentrations in subjects with hypercholesterolemia: A randomized placebo-controlled trial. <i>Journal of Dairy Science</i> , 2011, 94, 589-601.	3.4	11
95	Enigmatic action of ciclosporine a on the naloxone-precipitated morphine withdrawal syndrome in mice. <i>Neuroscience</i> , 1989, 31, 97-103.	2.3	10
96	The use of uniformly labelled substrates and mass isotopomer analysis to study intermediary metabolism. <i>Proceedings of the Nutrition Society</i> , 1994, 53, 345-354.	1.0	10
97	Effects of Lipid-Lowering Drugs on High-Density Lipoprotein Subclasses in Healthy Men—A Randomized Trial. <i>PLoS ONE</i> , 2014, 9, e91565.	2.5	10
98	Novel Approaches to the Pharmacotherapy of Obesity. <i>Current Pharmaceutical Design</i> , 2013, 19, 4938-4952.	1.9	9
99	Cardiovascular effects of endothelin 1 in pithed spontaneously hypertensive rats: evaluation of its mechanism(s) of action. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1989, 340, 424-430.	3.0	8
100	Daily Supplementation with 4000 IU Vitamin D3 for Three Years Does Not Modify Cardiovascular Risk Markers in Patients with Advanced Heart Failure: The Effect of Vitamin D on Mortality in Heart Failure Trial. <i>Annals of Nutrition and Metabolism</i> , 2019, 74, 62-68.	1.9	8
101	A 3-year post-intervention follow-up on mortality in advanced heart failure (EVITA vitamin D) Tj ETQq1 1 0.784314 rgBT /Overlock 1	3.1	8
102	Identification of cardiotoxic sodium channel activators by potassium depolarization in isolated guinea-pig atria. <i>Journal of Pharmacological Methods</i> , 1990, 24, 121-135.	0.7	7
103	Treatment of Cardiovascular Risk Factors in Women. <i>Current Medicinal Chemistry</i> , 2015, 22, 3580-3596.	2.4	7
104	Familial Hypercholesterolemia: Etiology, Diagnosis and New Treatment Options. <i>Current Pharmaceutical Design</i> , 2014, 20, 6220-6229.	1.9	6
105	Oral Contraceptives Moderately Effect Bone Resorption Markers and Serum-Soluble Interleukin-6 Receptor Concentrations. <i>Calcified Tissue International</i> , 2002, 70, 16-21.	3.1	5
106	Lipid lowering in patients with chronic kidney disease: a SHARP turn in the wrong direction?. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 858-861.	2.8	5
107	Evaluation of the Coroflex Theca-Stent for reduction of restenosis (ECORI). <i>Journal of Invasive Cardiology</i> , 2005, 17, 199-202.	0.4	5
108	Influence of Simvastatin on apoB <sub>100</sub> Secretion in Non-Obese Subjects with Mild Hypercholesterolemia. <i>Lipids</i> , 2010, 45, 491-500.	1.7	4

#	ARTICLE	IF	CITATIONS
109	Role of Physician Gender in the Quality of Care of Cardiometabolic Diseases. <i>Current Pharmaceutical Design</i> , 2011, 17, 3690-3698.	1.9	4
110	Lipoprotein apheresis in isolated hyperlipoproteinemia(a): a validated treatment or an illusion of validity?. <i>European Journal of Clinical Investigation</i> , 2013, 43, 108-112.	3.4	4
111	Pharmacologic Therapy for Cardiovascular Risk Reduction in Patients with the Metabolic Syndrome. <i>Current Pharmaceutical Design</i> , 2014, 20, 5025-5038.	1.9	4
112	Management of Blood Pressure and Heart Rate in Patients with Diabetes Mellitus. <i>Current Pharmaceutical Design</i> , 2017, 23, 4573-4582.	1.9	4
113	Atherosclerotic disease location and disparities in the control and treatment of cardiovascular risk factors in patients with Type 2 diabetes. <i>Diabetic Medicine</i> , 2010, 27, 303-308.	2.3	3
114	Reply to Meshkini et al.. <i>European Journal of Clinical Nutrition</i> , 2021, 75, 990-991.	2.9	3
115	Clinical and angiographic procedural and mid-term outcome with new versus reused balloon catheters in percutaneous coronary interventions. <i>Indian Heart Journal</i> , 2005, 57, 114-20.	0.5	2
116	Failure of the nonselective $\beta$ -blocker propranolol to affect lipoprotein lipase gene expression in the rat. <i>Lipids</i> , 1997, 32, 943-947.	1.7	1
117	Short-term vascular smooth muscle cells with platelet-derived growth factor (PDGF)-BB and angiotensin II induces stimulation of [ $^3$ H]thymidine incorporation without mitosis. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2000, 60, 723-731.	1.2	1
118	Restenosis Rates with Flexible GFX Stents (REFLEX): Clinical and angiographic Results. <i>Journal of Interventional Cardiology</i> , 2002, 15, 269-275.	1.2	1
119	Selenium and hypertension. <i>Journal of Hypertension</i> , 2013, 31, 1050-1052.	0.5	1
120	Mipomersen: a lipid-lowering agent with a novel mechanism of action. <i>Clinical Lipidology</i> , 2013, 8, 279-282.	0.4	1
121	Verwendung von [ $^{13}$ C]Laktose-Ureid in einem neuen Atemtest zur Bestimmung von intestinaler bakterieller Besiedlung und intestinaler Passagezeit. <i>Isotopes in Environmental and Health Studies</i> , 1992, 28, 32-32.	0.2	0
122	The Low Pressure Stent Observational Trial on the Procedural and Mid-Term Outcome of a Trapezoid-Shaped Coronary Stent (LOPSTER). <i>Journal of Interventional Cardiology</i> , 2005, 18, 323-329.	1.2	0
123	Lifibrol as a Model Compound for a Novel Lipid-Lowering Mechanism of Action. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2010, 15, 364-372.	2.0	0
124	The Role of Niacin in Lipid-lowering Treatment: Are we Aiming Too High?. <i>Current Pharmaceutical Design</i> , 2013, 999, 9-16.	1.9	0